Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 24

Results For "cancers"

349 News Found

Aster Hospitals Bangalore launches 'Aster International Institute of Oncology'
Healthcare | September 22, 2022

Aster Hospitals Bangalore launches 'Aster International Institute of Oncology'

This newly launched institute will be the centre of excellence in the treatment of all cancers under a single roof.


Zydus launches Lenalidomide Capsules
News | September 22, 2022

Zydus launches Lenalidomide Capsules

Lenalidomide is used to treat various types of cancers.


BridgeBio Pharma, Sentynl Therapeutics receive marketing authorization in the EU for fosdenopterin
Drug Approval | September 22, 2022

BridgeBio Pharma, Sentynl Therapeutics receive marketing authorization in the EU for fosdenopterin

NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.


Medical devices market in Singapore to reach $3.5 billion in 2022, forecasts GlobalData
News | September 21, 2022

Medical devices market in Singapore to reach $3.5 billion in 2022, forecasts GlobalData

Singapore presents great opportunities for the adoption of technology in healthcare and is open for investments


Zydus receives final approval from USFDA for Lenalidomide Capsules
Drug Approval | September 15, 2022

Zydus receives final approval from USFDA for Lenalidomide Capsules

The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India


InnoCare announces priority review of Orelabrutinib for the treatment of R/R MZL by NMPA
News | September 06, 2022

InnoCare announces priority review of Orelabrutinib for the treatment of R/R MZL by NMPA

Orelabrutinib is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases.


Yingli Pharma announces first patient dosed in Phase 2 Trial of Linperlisib for peripheral T Cell Lymphoma
Clinical Trials | September 05, 2022

Yingli Pharma announces first patient dosed in Phase 2 Trial of Linperlisib for peripheral T Cell Lymphoma

Phase 2 study to assess efficacy and safety of once daily linperlisib in patients with advanced peripheral T/NK cell lymphoma


Merck to present new data of oncology portfolio at ESMO 2022
Clinical Trials | August 30, 2022

Merck to present new data of oncology portfolio at ESMO 2022

Longer-term survival results underscoring role of KEYTRUDA (pembrolizumab) in multiple cancer types, including advanced nonsquamous non-small cell lung cancer (KEYNOTE-189)


Olaparib approved in Japan as adjuvant treatment for patients with high recurrent risk breast cancer
Drug Approval | August 26, 2022

Olaparib approved in Japan as adjuvant treatment for patients with high recurrent risk breast cancer

First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint of the OlympiA trial, in these patients


PM to inaugurate Amrita Hospital and Homi Bhabha Cancer Hospital & Research Centre
Policy | August 23, 2022

PM to inaugurate Amrita Hospital and Homi Bhabha Cancer Hospital & Research Centre

The hospital is being constructed at an estimated cost of around Rs. 6,000 crore and will provide healthcare facilities to the people of Faridabad and the entire NCR region